Phase 3 or bust: Why Lilly won't run mid-stage cancer trials

CHICAGO — Self-described “blunt pharma executives” Jake Van Naarden and David Hyman of Eli Lilly sat down Sunday with Endpoints News at the annual ASCO conference. The biggest takeaway from a conversation with the Indianapolis ...